DUG Foodtech announces the outcome of the rights issue
Reading Time: 7 minutes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR
OCBC Forms Strategic Partnership With Ant International to Enhance the Efficiency of Cross-Border Fund Settlements Through Innovations in Tokenised Deposits
Reading Time: 3 minutes Singapore: OCBC and Ant International have formed a strategic partnership to enhance the efficiency and speed of cross-border fund settlements. In a Memorandum of Understanding (MoU) signed on 5 November 2024 by Melvyn Low, Head of Global Transaction Banking at OCBC,and
Burjeel Holdings and Response Plus Medical launch $1mn Human Energy Health and Wellbeing Award
Reading Time: 3 minutes Abu Dhabi, United Arab Emirates: Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, and Response Plus Medical Services (RPM), the largest pre-hospital care and emergency medical services provider in the region, have jointly launched the $1 million Human
#24-379 Listing of Derivatives at NGM
Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market
#24-380 Delisting of Derivatives from NGM
Reading Time: < 1 minute Information about certain derivatives that will be delisted from NGM. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market NGM AB (NGM) is an authorized
BLA for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) accepted for priority review by the U.S. FDA
Reading Time: 2 minutes Stockholm, November 5, 2024: Immedica announces today that the Biologics License Application (BLA) for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) has been successfully validated and accepted for priority review by the U.S. Food and Drug Administration (FDA). Anders
DanCann Pharma A/S: Capital reduction in DanCann Pharma A/S is completed
Reading Time: 3 minutes The capital reduction in DanCann Pharma A/S as resolved on an extraordinary general meeting held on 7 October 2024 has been completed today, 5 November 2024, following expiry of a 4-week notice period (“proklama”). As set out in press release published
Noble Corporation plc Provides Guidance
Reading Time: < 1 minute SUGAR LAND, TEXAS, Nov. 5, 2024 /PRNewswire/ – Noble Corporation plc (“Noble”) (CSE: NOBLE, NYSE: NE) today provides guidance for the quarter ended December 31, 2024. In accordance with Danish legal and stock exchange requirements, Noble announced that for the quarter
Synsam invites you to a video presentation of the Q3 report 2024 and a live Q&A session
Reading Time: 2 minutes Synsam AB (publ) will release its interim report for the third quarter 2024 on Tuesday, November 19th at 07:30. At the same time, the company will publish an interview with President and CEO Håkan Lundstedt, together with a presentation of the
THOMSON IMPROVES ENERGY EFFICIENCY OF MEDIUM-DUTY APPLICATIONS WITH NEW 48-VOLT ELECTRIC LINEAR ACTUATOR
Reading Time: 3 minutes Editorial Contact: Shreyasi Bhaumik – +44 (0) 203 409 5090Company Contact: Kevin Bastian – +1 630 694 3342 Please quote the following contact information when publishing:Tel.: 540.633.3549, Fax: 540.633.0294, www.thomsonlinear.com; Thomson@regalrexnord.com 11.05.2024, DOWNERS GROVE, IL – Thomson Industries, Inc., a